🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Pasithea Therapeutics Stock Skyrockets On Nasal Spray Approval

Published 24/11/2021, 02:14 am
© Reuters.
KTTA
-

By Sam Boughedda

Investing.com — Shares of Pasithea Therapeutics Corp (NASDAQ:KTTA) have skyrocketed Tuesday after announcing that its subsidiary Pasithea Clinics has been approved to provide esketamine nasal spray (SPRAVATO) for treatment-resistant depression in adults.

Pasithea shares shot up 220%, to around $7.08

The biotechnology firm, which focuses on treatments for psychiatric and neurological disorders, said it has started offering the treatment in its Knightsbridge, London, location — becoming only one of three clinics in the U.K. approved to provide the treatment.

Pasithea CEO Dr. Tiago Reis Marques called the approval an "important milestone" for its U.K. clinics and their patients.

Last week, Pasithea revealed that Pasithea Clinics has launched an in-home intravenous ketamine therapy for patients suffering from similar treatment-resistant mental health issues. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.